title: Cerebellar alterations and gait defects as therapeutic outcome measures for enzyme replacement therapy in α-mannosidosis.
abstract: α-Mannosidosis is a rare lysosomal storage disease with accumulation of undegraded mannosyl-linked oligosaccharides in cells throughout the body, most notably in the CNS. This leads to a broad spectrum of neurological manifestations, including progressive intellectual impairment, disturbed motor functions, and cerebellar atrophy. To develop therapeutic outcome measures for enzyme replacement therapy that could be used for human patients, a gene knockout model of α-mannosidosis in mice was analyzed for CNS pathology and motor deficits. In the cerebellar molecular layer, α-mannosidosis mice display clusters of activated Bergman glia, infiltration of phagocytic macrophages, and accumulation of free cholesterol and gangliosides (GM1), notably in regions lacking Purkinje cells. α-Mannosidosis brain lysates also displayed increased expression of Lamp1 and hyperglycosylation of the cholesterol binding protein NPC2. Detailed assessment of motor function revealed age-dependent gait defects in the mice that resemble the disturbed motor function in human patients. Short-term enzyme replacement therapy partially reversed the observed cerebellar pathology with fewer activated macrophages and astrocytes but unchanged levels of hyperglycosylated NPC2, gangliosides, and cholesterol. The present study demonstrates cerebellar alterations in α-mannosidosis mice that relate to the motor deficits and pathological changes seen in human patients and can be used as therapeutic outcome measures.
authors.affiliation: Department of Biochemistry 2, Georg-August University Göttingen, Germany.
authors.forename: Markus
authors.initials: M
authors.lastname: Damme
authors.forename: Stijn
authors.initials: S
authors.lastname: Stroobants
authors.forename: Steven U
authors.initials: SU
authors.lastname: Walkley
authors.forename: Renate
authors.initials: R
authors.lastname: Lüllmann-Rauch
authors.forename: Rudi
authors.initials: R
authors.lastname: D'Hooge
authors.forename: Jens
authors.initials: J
authors.lastname: Fogh
authors.forename: Paul
authors.initials: P
authors.lastname: Saftig
authors.forename: Torben
authors.initials: T
authors.lastname: Lübke
authors.forename: Judith
authors.initials: J
authors.lastname: Blanz
mesh_terms: D000818:Animals; D016466:CHO Cells; D002531:Cerebellum / Q000201:enzymology* / Q000473:pathology* / Q000503:physiopathology; D006224:Cricetinae; D003412:Cricetulus; D004195:Disease Models, Animal; D056947:Enzyme Replacement Therapy / Q000379:methods*; D018390:Gene Targeting; D006801:Humans; D007794:Lameness, Animal / Q000188:drug therapy* / Q000201:enzymology* / Q000235:genetics; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D008818:Mice, Neurologic Mutants; D016896:Treatment Outcome; D043323:alpha-Mannosidase / Q000172:deficiency / Q000235:genetics; D008363:alpha-Mannosidosis / Q000188:drug therapy / Q000201:enzymology*
chemical_list: D043323:alpha-Mannosidase